T he U.S. Food and Drug Administration today approved Jevtana (cabazitaxel), a chemotherapy drug used in combination with the steroid prednisone to treat men with prostate cancer. Jevtana is the first treatment for advanced, hormone-refractory, prostate cancer that has worsened during or after ...
"The success of TULSA represents a revolution in whole-gland treatment forprostate cancer," said lead author Steven S. Raman, M.D., FASR, FSIR, professor of radiology, urology and surgery at the David Geffen School of Medicine at UCLA. "Prostate cancer is the most common form of cancer ...
For the first time, researchers have discovered that prostate cancer can be killed by targeting a single enzyme, called PI5P4Kα. The findings, published recently inScience Advances, could help address the growing threat of treatment resistance in prostate cancer and could also lead to improved t...
CHICAGO, June 4 (Xinhua) -- A combination of two existing prostate cancer therapies could extend lives of men with advanced, high-risk prostate cancer, a study showed. The addition of Zytiga to androgen-deprivation therapy can "significantly" increase overall survival in men with newly diagnosed,...
There have been three major new FDA approvals for prostate cancer diagnostics and treatments since the beginning of 2023: Akeega (niraparib and abiraterone acetate) – Janssen (August 2023) Treatment of adult patients with deleterious or suspected deleterious BRCA-positive mCRPC, as detected by an...
“represents a revolution in whole-gland treatment for prostate cancer.” “prostate cancer is the most common form of cancer in men, affecting one in eight men in their lifetime,” he said. “we have more research to do, but if validated, (ultrasound) has the ...
Prostate Cancer and Prostatic DiseasesBogdanos I,Karamanolakis D,Milathianakis C, et al.New strategies for the treatment of hormone-independent prostate cancer. J BUON . 2002Bogdanos et al. ' New strategies for the treatment of hormone-independent prostate cancer ', Journal of B.U.ON.: ...
In recent years the pace of research in prostate cancer has increased dramatically. Creative ideas in combination with new and emerging technologies have led to an explosion of discovery. These types of advances in prostate cancer research presage an era of new treatment strategies based on an unde...
Genome-wide association studies (GWAS) have identified ~170 genetic loci associated with prostate cancer (PCa) risk, but most of them were identified in European populations. We here performed a GWAS and replication study using a large Japanese cohort (9
000 die from prostate cancer (GLOBOCAN). There was over four times the incidence of prostate cancer in 2017 as in the 1950s, but at the same time, the treatments have been improving, so many more live longer, and die with, rather than of, prostate cancer. Nevertheless, more effective ...